Literaturverzeichnis 2015 und 2016

 

Hier finden Sie die Literaturangaben zu den Übersichtsartikeln der Zeitschrift für Infektionstherapie aus den Jahren 2015 und 2016

 

Reihenfolge:

 

2015

 

Heft 6 / 2015

Heft 5 / 2015

Heft 4 / 2015

Heft 3 / 2015

Heft 2 / 2015 (s. PDF Datei, Archiv)

Heft 1 / 2015 (s. PDF Datei, Archiv)

 

2016

 

Heft 6 / 2016

Heft 5 / 2016 (s. PDF Datei, Archiv)

Heft 4 / 2016

Heft 3 / 2016

Heft 2 / 2016

Heft 1 / 2016

Literaturangaben zum Übersichtsartikel aus

Heft 6 / 2015 der Zeitschrift für Infektionstherapie

Renaissance alter Antibiotika

1. Theuretzbacher U, Van Bambeke F, Cantón R, Giske CG, Mouton JW, Nation RL, Paul M, Turnidge JD, Kahlmeter G. Reviving old antibiotics. J Antimicrob Chemother. 2015 Aug;70(8):2177-81.

 

2. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 1;52(5):e103-20.

 

3. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother. 2012 Apr;56(4):2181-3.

 

4. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited. Int J Antimicrob Agents. 2012 Jan;39(1):45-51.

 

5. Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015 Sep;70(9):2456-64.

 

6. McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J Antimicrob Chemother. 1994 May;33 Suppl A:23-30.

 

7. Cunha BA. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. Med Clin North Am. 2006 Nov;90(6):1089-107. Review.

 

8. Gupta K, Hooton TM, Stamm WE. Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. J Antimicrob Chemother. 2005 Jul;56(1):243-6.

 

9: Sherigar JM, Fazio R, Zuang M, Arsura E. Autoimmune hepatitis induced by nitrofurantoin. The importance of the autoantibodies for an early diagnosis of immune disease. Clin Pract. 2012 Oct 17;2(4):e83.

 

10. Kothari A, Sagar V. Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study. J Infect Dev Ctries. 2008 Oct 1;2(5):354-8.

 

11. Sire JM, Nabeth P, Perrier-Gros-Claude JD, Bahsoun I, Siby T, Macondo EA, Gaye-Diallo A, Guyomard S, Seck A, Breurec S, Garin B. Antimicrobial resistance in outpatient Escherichia coli urinary isolates in Dakar, Senegal. J Infect Dev Ctries. 2007 Dec 1;1(3):263-8.

 

Literaturangaben zum Übersichtsartikel aus

Heft 5 / 2015 der Zeitschrift für Infektionstherapie

Neurotoxizität von Antibiotika

1. Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis. 2005 Oct;24(10):649-53. Review.

 

2. Toda A, Ohki H, Yamanaka T, Murano K, Okuda S, Kawabata K, Hatano K, Matsuda K, Misumi K, Itoh K, Satoh K, Inoue S. Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4849-52

 

3. Wong VK, Wright HT Jr, Ross LA, Mason WH, Inderlied CB, Kim KS. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J. 1991;10:122-5

 

4. Famularo G, Pizzicannella M, Gasbarrone L. Levofloxacin and seizures: what risk for elderly adults? J Am Geriatr Soc. 2014 Oct;62(10):2018-9. doi: 10.1111/jgs.13039.

 

5. Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. Clin Ther. 2014 Nov 1;36(11):1489-1511

 

6. Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010 Mar 1;27(3):193-209

 

7. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011 May 25;1(1):14

 

8. Fachinfo COLISTIMETHAT NATRIUM INFECTOPHARM, Juni 2013

www.fachinfo.de

 

9. Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ. Mental confusion in a patient treated with metronidazole--a concentration-related effect?

Pharmacotherapy  1982;2:384-7

 

10. Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations.

Br J Clin Pharmacol. 2011 Sep;72(3):381-93

 

11. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome.

Pharmacotherapy. 2007 Aug;27(8):1189-97

 

12. Toole JF, Parrish ML. Nitrofurantoin polyneuropathy. Neurology. 1973;23:554-9

 

13. Fachinfo NITROFURANTOIN ratiopharm retard,

Oktober 2014

www.fachinfo.de

 

Literaturangaben zum Übersichtsartikel aus

Heft 4 / 2015 der Zeitschrift für Infektionstherapie

Antibiotikatherapie bei geriatrischen Patienten

1. Pagani L. Appropriate antimicrobial therapy in the elderly: when half-size does not fit all frail patients. Clin Microbiol Infect. 2015 Jan;21(1):1-2

 

2. Suetens C. Healthcare-associated infections in European long-term care facilities: how big is the challenge? Euro Surveill. 2012 Aug 30;17(35). pii:20259

 

3. van Duin D. Diagnostic challenges and opportunities in older adults with infectious diseases. Clin Infect Dis. 2012 Apr;54(7):973-8

 

4. Wang L, Lansing B, Symons K, Flannery EL, Fisch J, Cherian K, McNamara SE, Mody L. Infection rate and colonization with antibiotic-resistant organisms in skilled nursing facility residents with indwelling devices. Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1797-804 FREE FULL TEXT

 

5. Beckett CL, Harbarth S, Huttner B. Special considerations of antibiotic prescription in the geriatric population. Clin Microbiol Infect. 2015 Jan;21(1):3-9

 

6. Corsonello A, Abbatecola AM, Fusco S, Luciani F, Marino A, Catalano S, Maggio MG, Lattanzio F. The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly. Clin Microbiol Infect. 2015 Jan;21(1):20-6

 

7. Mizuno T, Mizokami F, Fukami K, Ito K, Shibasaki M, Nagamatsu T, Furuta K. The influence of severe hypoalbuminemia on the half-life of vancomycin in elderly patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia. Clin Interv Aging. 2013;8:1323-8

 

8. Pereira JM, Paiva JA. Antimicrobial drug interactions in the critically ill patients. Curr Clin Pharmacol. 2013 Feb 1;8(1):25-38

 

9. Dyar OJ, Pagani L, Pulcini C. Strategies and challenges of antimicrobial stewardship in long-term care facilities. Clin Microbiol Infect. 2015 Jan;21(1):10-9

Literaturangaben zum Übersichtsartikel aus

Heft 3 / 2015 der Zeitschrift für Infektionstherapie

Antibiotikatherapie von MRSA-Infektionen

Literaturangaben zum Übersichtsartikel aus

Heft 6 / 2016 der Zeitschrift für Infektionstherapie

Therapie der nosokomialen und beatmungsassoziierten Pneumonien

1. Stevens JP, Kachniarz B, Wright SB, Gillis J, Talmor D, Clardy P, Howell MD. When policy gets it right: variability in u.s. Hospitals' diagnosis of ventilator-associated pneumonia*. Crit Care Med. 2014 Mar;42(3):497-503

 

2. Muscedere JG, Day A, Heyland DK. Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia. Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S120-5

 

3. Vincent JL, Bassetti M, François B, Karam G, Chastre J, Torres A, Roberts JA, Taccone FS, Rello J, Calandra T, De Backer D, Welte T, Antonelli M. Advances in antibiotic therapy in the critically ill. Crit Care. 2016 May 17;20(1):133

 

4. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents. 2014 Apr;43(4):328-34

 

5. Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF. In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother. 2016 Jul 22;60(8):4743-9

 

6. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016 Sep 1;63(5):575-82

 

7. Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J. Introduction to drug pharmacokinetics in the critically ill patient. Chest. 2012 May;141(5):1327-36

 

8. Abdul-Aziz MH, Dulhunty JM, Bellomo R, Lipman J, Roberts JA. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care. 2012 Aug 16;2(1):37. doi: 10.1186/2110-5820-2-37

 

9. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA. Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Ann Intensive Care. 2012 Jul 28;2(1):35

 

10. Wood GC. Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther. 2011 Nov;9(11):993-1000

 

11. Palmer LB, Smaldone GC. Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med. 2014 May 15;189(10):1225-33

 

Literaturangaben zum Übersichtsartikel aus

Heft 4 / 2016 der Zeitschrift für Infektionstherapie

Aktuelle Aspekte der Vancomycin-Therapie

1: Geffers C, Gastmeier P. Regionale Verteilung des Anteils von MRSA und VRE bei nosokomialen Infektionen mit S. aureus und Enterokokken. Epidem Bulletin 2016 Jun 6;22:191-193 (PDF-Datei)

 

2: Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients:  a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98. Erratum in: Am J Health Syst Pharm. 2009 May 15;66(10):887. PubMed PMID: 19106348.

 

3: Álvarez R, López Cortés LE, Molina J, Cisneros JM, Pachón J. Optimizing the Clinical Use of Vancomycin. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2601-9

 

4: Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, McNutt LA. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis. 2014 Sep 1;59(5):666-75

 

5: Rosini JM, Laughner J, Levine BJ, Papas MA, Reinhardt JF, Jasani NB. A randomized trial of loading vancomycin in the emergency department. Ann Pharmacother. 2015 Jan;49(1):6-13

 

6: Cristallini S, Hites M, Kabtouri H, Roberts JA, Beumier M, Cotton F, Lipman J, Jacobs F, Vincent JL, Creteur J, Taccone FS. A new regimen for continuous infusion of vancomycin in critically ill patients. Antimicrob Agents Chemother. 2016; 60:4750-4756

 

7: Hanrahan TP, Harlow G, Hutchinson J, Dulhunty JM, Lipman J, Whitehouse T, Roberts JA. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*. Crit Care Med. 2014 Dec;42(12):2527-36

 

8: Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother. 2011 Jun;55(6):2704-9

 

9: Escobar L, Andresen M, Downey P, Gai MN, Regueira T, Bórquez T, Lipman J, Roberts JA. Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration. Int J Antimicrob Agents. 2014 Aug;44(2):163-7

 

10: Bourguignon L, Cazaubon Y, Debeurme G, Loue C, Ducher M, Goutelle S. Pharmacokinetics of vancomycin in elderly patients aged over 80 years. Antimicrob Agents Chemother. 2016; 60:4563-4567

 

11: Reynolds DC, Waite LH, Alexander DP, DeRyke CA. Performance of a vancomycin dosage regimen developed for obese patients. Am J Health Syst Pharm. 2012 Jun 1;69(11):944-50

 

12: Karino S, Kaye KS, Navalkele B, Nishan B, Salim M, Solanki S, Pervaiz A, Tashtoush N, Shaikh H, Koppula S, Martin ET, Mynatt RP, Murray KP, Rybak MJ, Pogue JM. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship. Antimicrob Agents Chemother. 2016 May 23;60(6):3743-50

 

Literaturangaben zum Übersichtsartikel aus

Heft 3 / 2016 der Zeitschrift für Infektionstherapie

Therapie von Harnwegsinfektionen trotz „Resistenz“ der Erreger

1. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008 Nov;54(5):1164-75

 

2. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle  LE, Raz R, Schaeffer AJ, Soper DE; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 1;52(5):e103-20

 

3. Gágyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier  E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ. 2015 Dec 23;351:h6544

 

4. Gágyor I, Haasenritter J, Bleidorn J, McIsaac W, Schmiemann G, Hummers-Pradier E, Himmel W. Predicting antibiotic prescription after symptomatic treatment for urinary tract infection: development of a model using data from an RCT in general practice. Br J Gen Pract. 2016 Apr;66(645):e234-40

 

5. Heintz BH, Halilovic J, Christensen CL. Vancomycin-resistant enterococcal urinary tract infections. Pharmacotherapy. 2010 Nov;30(11):1136-49

 

6. Cole KA, Kenney RM, Perri MB, Dumkow LE, Samuel LP, Zervos MJ, Davis SL. Outcomes of Aminopenicillin Therapy for Vancomycin-Resistant Enterococcal Urinary Tract Infections. Antimicrob Agents Chemother. 2015 Dec;59(12):7362-6

 

7. Wenzler E, Danziger LH. Urinary Tract Infections: Resistance Is Futile. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2596-7

 

8. Stamey TA, Fair WR, Timothy MM, Millar MA, Mihara G, Lowery YC. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl  J Med. 1974 Nov 28;291(22):1159-63

 

9. Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA. 2005 Feb 23;293(8):949-55

 

10. Lee SS, Kim Y, Chung DR. Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis. J Infect. 2011 Feb;62(2):159-64

 

11. Yang YS, Ku CH, Lin JC, Shang ST, Chiu CH, Yeh KM, Lin CC, Chang FY. Impact of Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections. J Microbiol Immunol Infect. 2010 Jun;43(3):194-9

Literaturangaben zum Übersichtsartikel aus

Heft 2 / 2016 der Zeitschrift für Infektionstherapie

Antimykotika zur systemischen Therapie

Literaturangaben zum Übersichtsartikel aus

Heft 1 / 2016 der Zeitschrift für Infektionstherapie

Höhen und Tiefen in der Infektiologie der letzten 25 Jahre

1: Graham DY. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med. 1993;328:349-350

 

2: Hentschel E et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993;328:308-12

 

3: Fauci AS, Marston HD. Ending the HIV-AIDS Pandemic--Follow the Science. N Engl J Med. 2015 Dec 3;373(23):2197-9

 

4: Molina JM; ANRS IPERGAY Study Group. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015 Dec 3;373(23):2237-46

 

5: Klibanov OM, Gale SE, Santevecchi B. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann Pharmacother 2015 May;49(5):566-81

 

6: Cure S, Guerra I, Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat. 2015;22:882-9

 

7: Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, Curtis RC, Markowitz L; Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States. MMWR Morb Mortal Wkly Rep. 2014 Jul 25;63(29):620-4

 

8: Whitney CG et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006 Oct 28;368(9546):1495-502

 

10: Pilishvili T et al. Active Bacterial Core Surveillance/ Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41

 

11: Forstner C, Pletz MW. [Vaccinations from the pulmonologist's point of view]. Internist (Berl). 2015 Jul;56(7):838-46

 

12: Bonten MJ et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015 Mar 19;372(12):1114-25

 

13: McCarthy M. UN cannot be sued for alleged role in Haitian cholera outbreak, US judge rules. BMJ. 2015 Jan 13;350:h205

 

14: Assiri A et al. (KSA MERS-CoV  Investigation Team). Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013 Aug 1;369(5):407-16

 

15: Schneider E, Chommanard C, Rudd J, Whitaker B, Lowe L, Gerber SI. Evaluation of Patients under Investigation for MERS-CoV Infection, United States, January 2013-October 2014. Emerg Infect Dis. 2015 Jul;21(7):1220-3

 

16: Baize S et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 2014 Oct 9;371(15):1418-25

 

17: Stamm LV. Ebola Virus Disease: Rapid Diagnosis and Timely Case Reporting are Critical to the Early Response for Outbreak Control. Am J Trop Med Hyg. 2015;93(3):438-40

 

18. Crowcroft N S et al. Methicillin-resitant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Contr Hosp Epidemiol 1999;20:31-36

 

19. Tabah A et al.Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med 2012; 38:1930-1945  

 

20: Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A, Shields RK, Pasculle AW, Ernst RK, Doi Y. Colistin-resistant Acinetobacter baumannii: beyond carbapenem

resistance. Clin Infect Dis. 2015 May 1;60(9):1295-303

 

21. Lederberg J, McCray A. Ome sweet omics - a genealogical treasury of words. The Scientist 2001;15:8

 

22: Riiser A. The human microbiome, asthma, and allergy. Allergy Asthma Clin Immunol. 2015 Dec 10;11:35.

 

23: Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012 Sep 13;489(7415):220-30.

24: van Nood E et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407-15

Informationen für Ärzte und Apotheker zur rationalen Infektionstherapie

Die Zeitschrift für Infektionstherapie (bis 2015: "Zeitschrift für Chemo-therapie") erscheint im Jahr 2018 im 39. Jahrgang. Herausgeber und Redaktion sind bemüht, Sie kontinu-ierlich und aktuell über wichtige Entwicklungen im Bereich der Infektionstherapie zu informieren.

 

Die vollständigen, aktuellen Ausgaben der Zeitschrift sind nur im Abonnement erhältlich.

 

Nach 24 Monaten stehen die Hefte als PDF-Dateien  frei zur Verfügung (Frühere Ausgaben und Register).

 

Wir bieten Ihnen auf diesem Wege ebenfalls alle Artikel der Rubrik "Neueinführungen" und einige andere regelmäßige Beiträge aus der Zeitschrift an.

 

Letzte Aktualisierung dieser Seiten: 1. August 2018

Druckversion Druckversion | Sitemap
© Zeitschrift für Infektionstherapie